Scott Galloway says GLP-1 drugs are the ‘silver bullet’ for America’s problems, if we’re not ‘stupid enough’ to get in the way.
On June 12, SpaceX (NASDAQ: SPCX) had the largest IPO in history, making $75 billion (1) – but the shares are already falling (2). Entrepreneur and NYU professor Scott Galloway is not impressed.
“Making Nasdaq withdraw the requirements applied to all companies so far, so that it can force the index funds to buy shares, is aimed at the cannon to demand $ 75B in a business with a small float. The result is a price that does not reflect the fundamental value at all,” wrote Galloway on June 17 Medium of the post (3). “But I digress. This is not an investment, but a trade. So … where is the ‘investment’?”
You Must Read
Galloway says you should forget SpaceX stock and invest in GLP-1s instead.
“Five years ago, when Ozempic and Wegovy were first approved for weight loss, GLP-1s were seen as the silver bullet for obesity,” Galloway wrote. “Today, they are a full-fledged magazine with silver bullets aimed at obesity, addiction, cancer, asthma, and a growing list of other diseases and chronic conditions.”
Here’s what Galloway had to say about which GLP-1 manufacturers are making good money — and what needs to change to make GLP-1s even more successful.
Eli Lilly is doing very well in the GLP-1 market
Galloway says pharmaceutical company Eli Lilly is doing very well because of the weight loss drug.
He says Eli Lilly’s shares have seen a 418% increase in price since 2021, when GLP-1 is approved for weight loss. According to Eli Lilly’s price history page, the stock price was $276.22 at the end of 2021. At the end of 2025, its stock was worth $1,074.68 (4).
The company is currently working on a new GLP-1 drug, a combination drug with promising phase 3 results (5). If successful, the drug could help Eli Lilly’s stock rise even further.
In comparison, another GLP-1 creator Novo Nordisk has not seen the same level of success. Galloway says that Eli Lilly may have had a better time marketing directly to consumers.
“In the GLP-1 category, we’re seeing prices expand. If we lower the price, we get more users,” said Eli Lilly Chair and CEO David Ricks. “That’s the way we’re going.
Galloway also says that GLP-1s are almost as effective as subscriptions, because people who ride in them tend to stay in them.
